Compare Endeavour Silver Corp (EXK) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Pfizer Inc — how do they compare? Endeavour Silver Corp trades at $8.75 (market cap $2.46B), while Pfizer Inc trades at $27.75 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 64.9× Endeavour Silver Corp's market cap, and Pfizer Inc pays a 6.14% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and Pfizer Inc for 158 Days on average.
| EXK | PFE | |
|---|---|---|
Market Cap | $2.46B | $159.59B |
Volume | 5,827,665 | 30,937,010 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $29.02 |
52-Week Low | $7.07 | $23.67 |
Typical Hold Time | 25 Days | 158 Days |
Enterprise Value | $2.47B | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.32, down 4.04% on the day, amid a bearish technical signal. The company reported a net loss of $119.1M in 2025 but expects a significant turnaround in 2026 with projected net income of $66M. Recent news highlights operational progress at the Terronera and Kolpa mines, though temporary disruptions have occurred. Analyst consensus is strongly bullish with a $10.50 price target, but technical indicators show selling pressure.
The outlook is mixed: strong analyst support and projected profitability in 2026 present upside, but near-term technical weakness and operational risks like mine blockades pose challenges. The stock's valuation multiples are elevated relative to current earnings, requiring successful execution of growth plans to justify further gains.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
